 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12345678910111213...4142» |
- Pathologic Features and Residual Cancer Burden (RCB) after Neoadjuvant Endocrine Therapy (NET) in Hormone Receptor Positive Breast Cancer (HR+ BC) (Exhibit Hall; Poster Board Number: 34) - Feb 18, 2024 - Abstract #USCAP2024USCAP_2205;
NET before surgery induces similar pathologic changes in the tumor bed as NACT. Many pathologists do not report post NET specimens as they report post NACT specimens due to lack of awareness and clear guidelines.
- |||| Ibrance (palbociclib) / Pfizer
Trial primary completion date: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P3, N=496, Active, not recruiting, Sponsor: Alliance Foundation Trials, LLC.
Many pathologists do not report post NET specimens as they report post NACT specimens due to lack of awareness and clear guidelines. Trial primary completion date: Dec 2023 --> Apr 2024
- || amcenestrant (SAR439859) / Sanofi
Trial completion date, Monotherapy, Metastases: AMEERA-3: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P2, N=367, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Dec 2023 --> Apr 2024 Trial completion date: Dec 2023 --> Mar 2024
- | vistusertib (AZD2014) / AstraZeneca
Trial completion date, Combination therapy, Metastases: Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (clinicaltrials.gov) - Feb 15, 2024
P1/2, N=72, Active, not recruiting, Sponsor: Centre Leon Berard
Trial completion date: Dec 2023 --> Mar 2024 Trial completion date: Dec 2023 --> Dec 2024
- ||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial completion date, Metastases: FALCON: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (clinicaltrials.gov) - Feb 15, 2024
P3, N=462, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2023 --> Dec 2024
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Phase classification, Combination therapy, Metastases: DESTINY-Breast08: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 15, 2024
P1, N=139, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Dec 2023 --> Dec 2024 Phase classification: P1b --> P1
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
New trial, Metastases: A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=34, Recruiting, Sponsor: Second Affiliated Hospital of Soochow University
- | Orilissa (elagolix) / AbbVie
New P4 trial: Brain Blood Flow Responses to Stress: Sex Differences (clinicaltrials.gov) - Feb 15, 2024
P4, N=26, Recruiting, Sponsor: University of Wisconsin, Madison
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Journal: Development of an App for Symptom Management in Women With Breast Cancer Receiving Maintenance Aromatase Inhibitors: Protocol for a Mixed Methods Feasibility Study. (Pubmed Central) - Feb 15, 2024
P=N/A
Phase classification: P1b --> P1 This protocol describes a study investigating the feasibility, acceptability, and usability of the symptom management tool Bone@BC developed for patients with breast cancer with an endocrine aspect.
- | NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: Endocrine Response in Women With Invasive Lobular Breast Cancer (clinicaltrials.gov) - Feb 14, 2024
P2, N=201, Active, not recruiting, Sponsor: Priscilla McAuliffe
This protocol describes a study investigating the feasibility, acceptability, and usability of the symptom management tool Bone@BC developed for patients with breast cancer with an endocrine aspect. Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Mar 2024
- ||||| camizestrant (AZD9833) / AstraZeneca
Enrollment closed: SERENA-4: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (clinicaltrials.gov) - Feb 11, 2024
P3, N=1370, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Mar 2023 --> Mar 2024 Recruiting --> Active, not recruiting
- | anastrozole / Generic mfg., dutasteride capsule / Generic mfg.
Preclinical, Journal: Androgen and Estrogen ? Receptor Expression Enhances Efficacy of Antihormonal Treatments in Triple-Negative Breast Cancer Cell Lines. (Pubmed Central) - Feb 10, 2024
Thus, antihormonal treatments could be beneficial for TNBC therapies. This study clarifies the importance of steroid hormones in AR and ER?-positive cell lines of TNBC.
- | anastrozole / Generic mfg., tamoxifen / Generic mfg.
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. (Pubmed Central) - Feb 9, 2024
In this cost-effectiveness study, RRSO with or without RRM at varying optimal ages was cost-effective compared with nonsurgical strategies for individuals who carried BRCA1, BRCA2, PALB2, RAD51C, RAD51D, or BRIP1 PVs. These findings support personalizing risk-reducing surgery and guideline recommendations for individual CSG-specific OC and BC risk management.
- | anastrozole / Generic mfg.
Journal: A Case of Complete Remission in a Patient with Synchronous Double Cancers of the Breast and Lung (Pubmed Central) - Feb 6, 2024
Breast cancer is treated with anastrozole, thoracoscopic right upper lobectomy was performed for the lung cancer...The breast cancer has not recurred and is doing well 6 months after surgery. As for primary lung cancer, 19 months have passed since surgery, and the patient is in complete remission without recurrence.
- | anastrozole / Generic mfg., tamoxifen / Generic mfg., fulvestrant / Generic mfg.
Journal, Surgery: A Case of De Novo Stage ? Breast Cancer Successfully Treated with Surgery and Multiple Endocrine Therapies Over a Long Period of Time (Pubmed Central) - Feb 6, 2024
Generally, primary tumor resection of Stage ? breast cancer does not improve prognosis, but in this case it provided good local control and enabled long-term endocrine therapy, resulting in prolonged disease-free survival.
- Venclexta (venetoclax) / Roche, AbbVie
DOUBLE (TRANSPLANT) TROUBLE: SUCCESSFUL STEM CELL TRANSPLANT FOR ACUTE MYELOID LEUKEMIA IN A HEART TRANSPLANT RECIPIENT FOR ANTHRACYCLINE INDUCED CARDIOMYOPATHY (Moderated Poster Theater 10) - Jan 26, 2024 - Abstract #ACC2024ACC_1614;
We describe a successful multidisciplinary and multi-institutional treatment of a cardio-oncology patient who underwent OHT from cardiotoxicity with MSD HCT to manage her post-OHT AML. The balance and clinical challenges of immunosuppression and treatment of post-OHT malignancy and HCT are reviewed.
- Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
WHEN ALTERNATIVE HEALTH CLINICS GO WRONG; STRONG MUSCLES, WEAK HEART AND A CASE OF ANABOLIC STEROID ASSOCIATED CARDIOMYOPATHY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_1370;
Our case highlights the risks of prescription hormone therapy, unmonitored by an appropriately qualified medical professional. Given the burgeoning societal interest in supplements and mushrooming clinics, appropriate oversight is necessary to preempt complications.
- | New P3 trial: SWE-Switch: Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (clinicaltrials.gov) - Jan 25, 2024
P3, N=3832, Not yet recruiting, Sponsor: Region
- |||| giredestrant (GDC-9545) / Roche
Enrollment open: PREcoopERA: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (clinicaltrials.gov) - Jan 25, 2024
P2, N=220, Recruiting, Sponsor: ETOP IBCSG Partners Foundation
Given the burgeoning societal interest in supplements and mushrooming clinics, appropriate oversight is necessary to preempt complications. Not yet recruiting --> Recruiting
- | anastrozole / Generic mfg.
Journal: Authorization of anastrazole to prevent breast cancer in postmenopausal women: a bad idea. (Pubmed Central) - Jan 24, 2024
When given to high-risk women anastrazole halves the risk of developing breast cancer but doesn't reduce the risk of breast cancer death and is associated with significant harms. Women need to be counselled about both the benefits and risks associated with anastrazole use to enable an informed treatment choice.
- |||||| Orserdu (elacestrant) / Menarini
Enrollment open: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (clinicaltrials.gov) - Jan 24, 2024
P3, N=220, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Women need to be counselled about both the benefits and risks associated with anastrazole use to enable an informed treatment choice. Not yet recruiting --> Recruiting
- ||| Review, Journal, Adverse events: Ocular Surface Side Effects of Novel Anticancer Drugs. (Pubmed Central) - Jan 23, 2024
However, the potential processes involved in the development of these alterations are yet not fully understood, especially for novel drugs currently available for cancer treatment. This review aims at analyzing the potential ocular surface and adnexal side effects of novel anticancer medications, trying to provide a better understanding of the underlying pharmacological processes and useful insights on the choice of proper management.
- | Hiltonol (poly-ICLC) / Oncovir
New P1 trial: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov) - Jan 23, 2024
P1, N=50, Not yet recruiting, Sponsor: Finn, Olivera, PhD
- | Enrollment change, Trial withdrawal: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Jan 23, 2024
P1, N=0, Withdrawn, Sponsor: OHSU Knight Cancer Institute
This review aims at analyzing the potential ocular surface and adnexal side effects of novel anticancer medications, trying to provide a better understanding of the underlying pharmacological processes and useful insights on the choice of proper management. N=25 --> 0 | Not yet recruiting --> Withdrawn
- Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer () - Jan 22, 2024 - Abstract #YIR2024YIR_137;
These data support a model whereby ER and RAS signaling converge upon CDK4/6, and CDK4/6 activation is a key survival mechanism when ER signaling is attenuated by treatment in NF1-depleted ER+ breast cancer cells. This apparent addiction for CDK4/6 activity makes NF1-depleted ER+ breast tumors vulnerable to CDK4/6 inhibition, thus creating a potential therapeutic opportunity to match CDK4/6 inhibition with patients who can benefit the most.
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trastuzumab deruxtecan (T-DXd) in combination with anastrozole or fulvestrant in patients with HER2-low HR+ advanced/metastatic breast cancer: a Phase 1b, open-label, multicenter, dose-expansion study (DESTINY-Breast08) () - Jan 22, 2024 - Abstract #YIR2024YIR_127;
P1b
Safety profiles for T-DXd-ET combinations were generally comparable to T-DXd monotherapy and manageable with dose modification and routine clinical practice. T-DXd in combination with anastrozole or fulvestrant was active in first- or second-line treatment of patients with HER2low HR+ mBC.
- Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE) () - Jan 22, 2024 - Abstract #YIR2024YIR_111;
The combination provides a chemotherapy-free alternative for pts with triple positive breast cancers. Further follow up will determine impact on PFS Table 1.
- Kisqali (ribociclib) / Novartis
Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2? early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial () - Jan 22, 2024 - Abstract #YIR2024YIR_30;
Efficacy results confirm continued improvement in benefit across subgroups, including stage II disease. Safety findings support the manageable toxicity profile of RIB at the 400-mg starting dose in early breast cancer.
- Kisqali (ribociclib) / Novartis
Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial () - Jan 22, 2024 - Abstract #YIR2024YIR_29;
P3
The NATALEE results support ribociclib + ET as the treatment of choice in a broad population of pts with stage II or III HR+/HER2? EBC, including pts with N0 disease
- Kisqali (ribociclib) / Novartis
Invasive disease-free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC) () - Jan 22, 2024 - Abstract #YIR2024YIR_28;
EBC were randomized 1:1 to RIB for 3 y (400 mg/d for 3 wk on/1 wk off ) + NSAI for ?5 y (letrozole 2.5 mg/d or anastrozole 1 mg/d) or NSAI alone. Premenopausal women and men received goserelin every 28 d. NATALEE included pts with anatomical stage IIA (N0 requiring additional risk factors or N1 [1-3 axillary lymph nodes]) and all pts with stage IIB or III disease per AJCC
- | anastrozole / Generic mfg.
Journal: Anastrozole Protects against Human Coronavirus Infection by Ameliorating the Reactive Oxygen Species-Mediated Inflammatory Response. (Pubmed Central) - Jan 22, 2024
Overall, we demonstrated that AZ exhibits antiviral activity against HCoV-OC43 and HCoV-229E. We specifically focused on its efficacy against HCoV-OC43 and showed its potential to reduce inflammation, inhibit NLRP3 inflammasome activation, mitigate mitochondrial dysfunction, and suppress pyroptosis in infected cells.
- | Verzenio (abemaciclib) / Eli Lilly
Enrollment change, Metastases: AMBRE: Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (clinicaltrials.gov) - Jan 22, 2024
P3, N=180, Recruiting, Sponsor: UNICANCER
We specifically focused on its efficacy against HCoV-OC43 and showed its potential to reduce inflammation, inhibit NLRP3 inflammasome activation, mitigate mitochondrial dysfunction, and suppress pyroptosis in infected cells. N=378 --> 180
- || vepdegestrant (ARV-471) / Arvinas, Pfizer
Enrollment closed, Surgery: TACTIVE-N: A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (clinicaltrials.gov) - Jan 21, 2024
P2, N=152, Active, not recruiting, Sponsor: Arvinas Inc.
N=378 --> 180 Recruiting --> Active, not recruiting
- ||| anastrozole / Generic mfg., fulvestrant / Generic mfg.
Clinical, P3 data, Journal: Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. (Pubmed Central) - Jan 18, 2024
P3
Differential NET response by PAM50 subtype in exploratory analyses warrants further investigation. ClinicalTrials.gov Identifier: NCT01953588.
- ||| giredestrant (GDC-9545) / Roche
Trial initiation date: PREcoopERA: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (clinicaltrials.gov) - Jan 18, 2024
P2, N=220, Not yet recruiting, Sponsor: ETOP IBCSG Partners Foundation
ClinicalTrials.gov Identifier: NCT01953588. Initiation date: Dec 2023 --> Mar 2024
- | letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Journal: An Updated Insight into Phytomolecules and Novel Approaches used in the Management of Breast Cancer. (Pubmed Central) - Jan 17, 2024
The current literature helps to know the available drugs i.e. phytoconstituents or novel drug delivery like nanoparticle, microsphere, micelles, liposomes and neosomes. The literature has been taken from PubMed, Google Scholar, SciFinder, or other internet sites.
- | Enrollment closed, Trial primary completion date: POWER: Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer (clinicaltrials.gov) - Jan 16, 2024
P2, N=83, Active, not recruiting, Sponsor: Shayna Showalter, MD
The literature has been taken from PubMed, Google Scholar, SciFinder, or other internet sites. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Mar 2024
- | Reimbursement, US reimbursement, Journal, Medicare, Adherence: Factors associated with adherence to medications for lowering breast cancer risk between female Medicare beneficiaries in Alabama and nationwide. (Pubmed Central) - Jan 15, 2024
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Mar 2024 Our findings highlight the importance of access to preventive services such as mammography to better adherence to BC preventive treatments among female Medicare beneficiaries.
- | Biomarker, Trial completion date, Trial initiation date, Trial primary completion date: NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Jan 9, 2024
P2, N=81, Not yet recruiting, Sponsor: Washington University School of Medicine
Our findings highlight the importance of access to preventive services such as mammography to better adherence to BC preventive treatments among female Medicare beneficiaries. Trial completion date: May 2027 --> Aug 2027 | Initiation date: Nov 2023 --> Feb 2024 | Trial primary completion date: May 2027 --> Aug 2027
- | anastrozole / Generic mfg.
Journal: Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. (Pubmed Central) - Jan 8, 2024
These results suggest that serum hormones should be measured more routinely and integrated into risk management decisions. Measuring serum hormone concentrations is inexpensive and might help clinicians differentiate which women will benefit most from an aromatase inhibitor.
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Jan 1, 2024
P=N/A, N=109, Completed, Sponsor: Mayo Clinic
Measuring serum hormone concentrations is inexpensive and might help clinicians differentiate which women will benefit most from an aromatase inhibitor. Active, not recruiting --> Completed
- | Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
Trial completion date, Trial primary completion date: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) - Dec 31, 2023
P2, N=48, Recruiting, Sponsor: Ruth O'Regan
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) - Dec 31, 2023
P2, N=19, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
- || Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date: Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) - Dec 28, 2023
P4, N=137, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Feb 2028 --> Sep 2029 | Trial primary completion date: Jan 2028 --> Aug 2029
- | anastrozole / Generic mfg.
Enrollment open: Study of 18F-FFNP Breast PET/MRI (clinicaltrials.gov) - Dec 27, 2023
P2, N=53, Recruiting, Sponsor: University of Wisconsin, Madison
Trial completion date: Feb 2028 --> Sep 2029 | Trial primary completion date: Jan 2028 --> Aug 2029 Not yet recruiting --> Recruiting
- |||| Eligard (leuprolide acetate) / Tolmar, Sanofi
Trial completion date, Trial primary completion date: Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study (clinicaltrials.gov) - Dec 22, 2023
P3, N=250, Enrolling by invitation, Sponsor: Tolmar Inc.
- | Verzenio (abemaciclib) / Eli Lilly
New P2 trial: Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (clinicaltrials.gov) - Dec 20, 2023
P2, N=60, Not yet recruiting, Sponsor: University of Washington
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - Dec 20, 2023
P2, N=84, Active, not recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial completion date: Apr 2027 --> Aug 2026
- |||||| defactinib (VS-6063) / Verastem, avutometinib (VS-6766) / Verastem
Enrollment open: RAMP 301: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - Dec 19, 2023
P3, N=270, Recruiting, Sponsor: Verastem, Inc.
Trial completion date: Apr 2027 --> Aug 2026 Not yet recruiting --> Recruiting
- | limantrafin (CB-103) / Cellestia Biotech
Enrollment change, Trial termination: CAILA: CB-103 Plus NSAI In Luminal Advanced Breast Cancer (clinicaltrials.gov) - Dec 19, 2023
P2, N=2, Terminated, Sponsor: MedSIR
Not yet recruiting --> Recruiting N=80 --> 2 | Active, not recruiting --> Terminated; Sponsor decision